Overview
Timothy Flerlage is an Infectious Disease provider practicing medicine in Rochester, New York.
His clinical expertise encompasses Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL).
He is actively involved in clinical research, co-authoring 1 peer reviewed article.
Specialties
Licenses
Languages Spoken
Gender
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- OTHER MEDICAID
- STATE MEDICAID
Locations
601 Elmwood Ave, Rochester, NY 14642
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
University Of Rochester
John Treanor is an Infectious Disease provider practicing medicine in Rochester, New York. Dr. Treanor is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Flu, H1N1 Influenza, Avian Influenza, and Severe Acute Respiratory Syndrome (SARS).
Rochester General Hospital
Ann Falsey is an Infectious Disease provider practicing medicine in Rochester, New York. Dr. Falsey is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Respiratory Syncytial Virus (RSV) Infection, Parainfluenza, Flu, and Severe Acute Respiratory Syndrome (SARS).
University Of Rochester
Angela Branche is an Infectious Disease provider practicing medicine in Rochester, New York. Dr. Branche is highly rated in 5 conditions, according to our data. Her clinical expertise encompasses Respiratory Syncytial Virus (RSV) Infection, Parainfluenza, Flu, and Asymptomatic Bacteriuria.
Frequently Asked Questions about Dr. Timothy Flerlage
How do I make an appointment with Dr. Timothy Flerlage?
You can book an appointment with Dr. Timothy Flerlage by calling their office at 585-275-5944. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.
Is Dr. Timothy Flerlage a top-rated expert for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)?
MediFind is an objective health platform that identifies experts based on real-world data. Dr. Timothy Flerlage is classified as an Experienced expert for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
What conditions does Dr. Timothy Flerlage specialize in?
While Dr. Timothy Flerlage is a Infectious Disease, they have specific expertise in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Infectious Disease.
Does Dr. Timothy Flerlage participate in research or clinical trials?
Yes. Dr. Timothy Flerlage has published 1 articles and abstracts on conditions like Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). You can view a list of Dr. Timothy Flerlage's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Does Dr. Timothy Flerlage accept my insurance?
Dr. Timothy Flerlage accepts most major insurance plans, including Blue Cross Blue Shield and Humana. We recommend calling the office directly at 585-275-5944 to verify that your specific plan is currently accepted before your visit.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)